Entropy Neurodynamics Limited has released a press release.
December Quarterly Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- First Dosing in PLEXOVAL Exosome Wound Healing Human Study
- Key Management Contracts Extended
- Development Program Update
- Appointment of Chief Commercial Officer
- Appendix 4C - quarterly
Later from Entropy Neurodynamics
- Independent Plexaris and Cevaris testing
- Cevaris testing shows positive results in models of ED
- Cevaris testing shows positive results in bladder control
- Appendix 4D and Interim Financial Report
- PLEXOVAL I study disrupted by the Covid-19 response
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics